Prylińska-Jaśkowiak Monika, Tabisz Hanna, Kujawski Sławomir, Godlewska Beata R, Słomko Joanna, Januszko-Giergielewicz Beata, Murovska Modra, Morten Karl J, Sokołowski Łukasz, Zalewski Paweł
Department of Exercise Physiology and Functional Anatomy, Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Toruń, Świętojańska 20, Bydgoszcz, 85-077, Poland.
Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK.
Sci Rep. 2025 Sep 26;15(1):33075. doi: 10.1038/s41598-025-16438-y.
The pathogenesis of Chronic Fatigue Syndrome (CFS) is yet unknown. This study aimed to assess the gut microbial composition in CFS patients versus in healthy controls (HCs). The composition of fecal bacteria was examined in twenty-five CFS patients and sixteen HCs using Illumina sequencing of 16 S rRNA gene amplicons targeting the V3-V4 bacterial gene regions. 143 (46%) of the microbial genera were found only in the CFS. In addition, the gut microbial composition in the CFS patients contained a much higher proportion of the 10 most commonly found bacteria compared to the HCs group. A significantly lower observed number of operational taxonomic units (OTUs) was noted in CFS compared to HCs (p = 0.045). Significant between-group differences in the gut microbial composition in CFS compared to HCs were noted. The three most discriminating Amplicon Sequencing Variants (ASVs): ASV 191, ASV 44, and ASV 75, were identified as significantly more abundant in the healthy control group compared to the patient group. In addition, the Neural Network (multilayer perceptron) was able to discriminate gut microbial composition from CFS versus HCs with excellent performance (AUC = 0.935). The gut microbial composition is different in CFS patients compared to HCs. Further studies should assess the pathophysiological consequences of these differences as well as the effectiveness of therapies aimed at modifying the gut microbial composition in CFS patients.
慢性疲劳综合征（CFS）的发病机制尚不清楚。本研究旨在评估CFS患者与健康对照者（HCs）的肠道微生物组成。使用针对V3-V4细菌基因区域的16S rRNA基因扩增子的Illumina测序，对25名CFS患者和16名HCs的粪便细菌组成进行了检测。143个（46%）微生物属仅在CFS患者中被发现。此外，与HCs组相比，CFS患者的肠道微生物组成中10种最常见细菌的比例要高得多。与HCs相比，CFS患者的可操作分类单元（OTUs）观察数量显著更低（p = 0.045）。与HCs相比，CFS患者的肠道微生物组成存在显著的组间差异。三种最具区分性的扩增子测序变体（ASVs）：ASV 191、ASV 44和ASV 75，被确定在健康对照组中比患者组更为丰富。此外，神经网络（多层感知器）能够以优异的性能区分CFS患者与HCs的肠道微生物组成（AUC = 0.935）。与HCs相比，CFS患者的肠道微生物组成有所不同。进一步的研究应评估这些差异的病理生理后果以及旨在改变CFS患者肠道微生物组成的治疗方法的有效性。
